Fate Therapeutics (NASDAQ:FATE) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, December 1st.
Several other equities analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, October 12th. Leerink Swann restated an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Friday, September 8th. Zacks Investment Research downgraded shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, BMO Capital Markets restated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $6.79.
Shares of Fate Therapeutics (FATE) opened at $4.65 on Friday. Fate Therapeutics has a 1-year low of $2.40 and a 1-year high of $5.68. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.21 and a quick ratio of 7.21.
Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The company had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.95 million. The company’s revenue was up .0% on a year-over-year basis. research analysts forecast that Fate Therapeutics will post -0.99 EPS for the current fiscal year.
In other news, insider Daniel D. Shoemaker sold 13,225 shares of Fate Therapeutics stock in a transaction on Monday, October 16th. The shares were sold at an average price of $3.87, for a total transaction of $51,180.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $3.85, for a total transaction of $31,150.35. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in FATE. State Street Corp purchased a new stake in shares of Fate Therapeutics during the 2nd quarter worth $1,437,000. Northern Trust Corp lifted its position in Fate Therapeutics by 968.7% in the second quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock valued at $1,193,000 after acquiring an additional 333,753 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Fate Therapeutics by 479.6% in the first quarter. Goldman Sachs Group Inc. now owns 144,053 shares of the biopharmaceutical company’s stock valued at $655,000 after acquiring an additional 119,200 shares during the last quarter. TIAA CREF Investment Management LLC purchased a new stake in Fate Therapeutics in the second quarter valued at $373,000. Finally, Vanguard Group Inc. lifted its position in Fate Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock valued at $4,096,000 after acquiring an additional 108,602 shares during the last quarter. 60.97% of the stock is owned by institutional investors and hedge funds.
WARNING: “Fate Therapeutics (FATE) Stock Rating Lowered by ValuEngine” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/14/valuengine-lowers-fate-therapeutics-fate-to-sell.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.